SCHEMBL4294652

SCHEMBL4294652

COC(=O)c1c[c]ccc1OC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
HSD17B10 Q99714 4/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
ALDH1A1 P00352 2/20 0.42
ESR1 P03372 1/20 0.42
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
HMGB1 P09429 1/20 0.42
GGT1 P19440 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
BLM P54132 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
SLC6A3 Q01959 1/20 0.41
CFD P00746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6195395 0.87 SLC6A3 (0.40) KDM4EHSD17B10HPGDTSHRALDH1A1
SCHEMBL4286291 0.87 KDM4E (0.43) KDM4EHSD17B10HPGDTSHRALDH1A1
SCHEMBL2443988 0.84 GAA (0.45) KDM4EHSD17B10HPGDTSHRALDH1A1
SCHEMBL6200251 0.83 KDM4E (0.58) KDM4EHSD17B10HPGDTSHRALDH1A1
SCHEMBL6201090 0.80 SLC6A3 (0.37) KDM4EHSD17B10HPGDTSHRALDH1A1
SCHEMBL4286287 0.79 IRAK4 (0.42) KDM4EHSD17B10TSHRALDH1A1TDP1
SCHEMBL4284044 0.79 KMT2A (0.50) KDM4EHSD17B10HPGDTSHRALDH1A1
SCHEMBL1451808 0.78 KDM4E (0.44) KDM4EHSD17B10HPGDTSHRALDH1A1
SCHEMBL130031 0.78 TSHR (0.44) KDM4EHSD17B10HPGDTSHRALDH1A1
SCHEMBL6200854 0.78 CHEK1 (0.41) KDM4EHSD17B10HPGDTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3878837-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS OM Pharma SA (CH) 2021-09-15 EP disclosed
US-8202880-B2 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors NYCOMED GMBH (DE) 2012-06-19 US disclosed
US-7632844-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2009-12-15 US disclosed
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors NYCOMED GMBH (DE) 2009-07-02 US disclosed
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH 2008-12-25 US disclosed
US-7423046-B2 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors NYCOMED GMBH (DE) 2008-09-09 US disclosed
US-7329676-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2008-02-12 US disclosed
US-20070259909-A1 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors ALTANA PHARMA AG (DE) 2007-11-08 US disclosed
CN-1926112-A Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors ALTANA PHARMA AG (DE) 2007-03-07 CN disclosed
EP-1536798-B1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2007-02-07 EP disclosed
EP-1539164-B1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2006-12-20 EP disclosed
EP-1725532-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors ALANA PHARMA AG (DE) 2005-10-27 US disclosed
US-20050239817-A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors ALTANA PHARMA AG (DE) 2005-10-27 US disclosed
WO-2005085203-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO disclosed
EP-1539164-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-15 EP disclosed
EP-1536798-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-08 EP disclosed
WO-2004019944-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
WO-2004019945-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239817-A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors PDE4A, PDE4B, PDE3A KDM4E 343/4885HSD17B10 353/4885HPGD 302/4885
US-20070259909-A1 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors PDE4A, PDE4B, PDE4D KDM4E 138/4885HSD17B10 278/4885HPGD 684/4885
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors PDE4A, PDE4B, PDE3A KDM4E 343/4885HSD17B10 353/4885HPGD 302/4885
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors PDE4A, PDE4B, PDE3A KDM4E 350/4885HSD17B10 382/4885HPGD 385/4885
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors PDE4A, PDE4B, PDE3A KDM4E 431/4885HSD17B10 290/4885HPGD 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.